Johnson & Johnson EBIT 2012-2026 | JNJ

Johnson & Johnson EBIT for the quarter ending March 31, 2026 was $5.947B, a 58.02% decline year-over-year.

  • Johnson & Johnson 2025 EBIT was 34.608B, a 84.34% increase from 2024.
  • Johnson & Johnson 2024 EBIT was 18.774B, a 9.82% increase from 2023.
  • Johnson & Johnson 2023 EBIT was 17.095B, a 15.06% decline from 2022.

EBIT can be defined as earnings before interest and taxes.

Johnson & Johnson EBIT 2012-2026 | JNJ

  • Johnson & Johnson 2025 EBIT was 34.608B, a 84.34% increase from 2024.
  • Johnson & Johnson 2024 EBIT was 18.774B, a 9.82% increase from 2023.
  • Johnson & Johnson 2023 EBIT was 17.095B, a 15.06% decline from 2022.

EBIT can be defined as earnings before interest and taxes.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$887.6B
AbbVie (ABBV)$367.7B
Roche Holding AG (RHHBY)$318.8B
Merck (MRK)$299.9B
Novartis AG (NVS)$294B
Novo Nordisk (NVO)$167.5B
Pfizer (PFE)$153.1B
Sanofi (SNY)$114B
Bayer (BAYRY)$46.2B
Innoviva (INVA)$1.8B